Juno Therapeutics to Highlight New Advances in CD19- and BCMA-Targeted CAR T Therapy at ASH With 15 Abstracts, Notably JCAR017 Data At Dose 2 Level That Showed 80% ORR Rate And 73% CR Rate At 3 Months In Core Group